WASHINGTON — The U.S. Food and Drug Administration put out the following message on June 25, 2021, regarding updated actions being taken against COVID-19. The message includes a new revision to provider fact sheets including “suggested increased risks” of inflammation to vaccine recipient’s hearts and surrounding heart tissue.

The full extent of increased risk is not fully clear from the FDA statements, and may change with future data. The CDC has previously seen a rough total of 1,200 cases of myocarditis or pericarditis out of the 300 million vaccines that have been administered as of June 11. This totals an average of 12.6 cases per million doses.

Other details not relating the inflammation issue were also mentioned in the full release.

Full Release:

“The U.S. Food and Drug Administration (FDA) continued to take action in the ongoing response to the COVID-19 pandemic:

[The] FDA is announcing revisions to the patient and provider fact sheets for the Moderna and Pfizer-BioNTech COVID-19 vaccines regarding the suggested increased risks of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the tissue surrounding the heart) following vaccination. For each vaccine, the Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) has been revised to include a warning about myocarditis and pericarditis and the Fact Sheet for Recipients and Caregivers has been revised to include information about myocarditis and pericarditis. This update follows an extensive review of information and the discussion by CDC’s Advisory Committee on Immunization Practices meeting on Wednesday. The data presented at this meeting reinforced the FDA’s decision to revise the fact sheets and further informed the specific revisions.

The warning in the Fact Sheets for Healthcare Providers Administering Vaccines notes that reports of adverse events suggest increased risks of myocarditis and pericarditis, particularly following the second dose and with onset of symptoms within a few days after vaccination. Additionally, the Fact Sheets for Recipients and Caregivers for these vaccines note that vaccine recipients should seek medical attention right away if they have chest pain, shortness of breath, or feelings of having a fast-beating, fluttering, or pounding heart after vaccination. The FDA and CDC are monitoring the reports, collecting more information, and will follow-up to assess longer-term outcomes over several months.


[As of June 25], the FDA issued a supplement to the 2015 safety communication on reprocessed flexible bronchoscopes, reminding health care facilities to follow manufacturer instructions for reprocessing and device maintenance, and providing a new recommendation for health care providers on single-use bronchoscopes. The goal of the recommendations is to reduce potential infection transmission between patients. This communication also includes updated information on medical device adverse event reports.


The FDA reached a milestone of approving 1,000 original and supplemental generic drug applications to help in the treatment of patients with COVID-19 since the start of the pandemic. The Center for Drug Evaluation and Research prioritized the review of generic drug applications for potential treatments and supportive therapies for patients with COVID-19, such as antibiotics, sedatives used in ventilated patients, anticoagulants, and pulmonary medications. Reaching this milestone during the COVID-19 pandemic further supports the FDA’s everyday mission of improving access to safe, high-quality treatment options, which can result in more competition in the market and more affordable medicines for Americans.

As part of the FDA’s effort to protect consumers, on June 22, 2021, the agency issued a warning letter to Pacific Center of Health/Pacific Center of Health & Acupuncture for selling unapproved products with unproven COVID-19 claims. Consumers concerned about COVID-19 should consult with their health care provider.
Testing updates:

As of [June 25], 389 tests and sample collection devices are authorized by the FDA under emergency use authorizations (EUAs). These include 278 molecular tests and sample collection devices, 83 antibody and other immune response tests and 28 antigen tests. There are 52 molecular authorizations and one antibody authorization that can be used with home-collected samples. There is one molecular prescription at-home test, three antigen prescription at-home tests, five antigen over-the-counter (OTC) at-home tests and two molecular OTC at-home tests.

The FDA has authorized 11 antigen tests and three molecular tests for serial screening programs. The FDA has also authorized 544 revisions to EUA authorizations.”

Related Information

 

Contact our news desk at news@thebaynet.com